Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tildacerfont

Generic Name: Tildacerfont

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₆ClN_₅OS

CAS Number: 1014983-00-6

Unique Ingredient Identifier: 09QCEV5481

Overview

Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring

Background

Tildacerfont is a corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens

Phase 2

Completed

Posted: 2022/05/11

Sponsor:Spruce Biosciences

ID:NCT05370521

A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH

Phase 2

Terminated

Posted: 2021/11/22

Sponsor:Spruce Biosciences

ID:NCT05128942

Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia

Phase 2

Completed

Posted: 2018/09/27

Sponsor:Spruce Biosciences

ID:NCT03687242

Study of SPR001 in Adults with Classic Congenital Adrenal Hyperplasia

Phase 2

Completed

Posted: 2017/08/22

Sponsor:Spruce Biosciences

ID:NCT03257462

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Spruce Biosciences Acquires Tralesinidase Alfa for Sanfilippo Syndrome Type B Treatment with BLA Submission Planned for 2026

a month ago

Spruce Biosciences has acquired tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B, a neurodegenerative and fatal genetic disease with no FDA-approved treatments.

FDA Grants Priority Review to Crinecerfont for Congenital Adrenal Hyperplasia

8 months ago

The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy